Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALLR NASDAQ:CTXR NASDAQ:GELS NASDAQ:REVB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLRAllarity Therapeutics$0.97-1.7%$0.97$0.61▼$6.00$14.87M0.08522,002 shs285,587 shsCTXRCitius Pharmaceuticals$1.23-4.7%$1.38$0.65▼$23.22$13.72M1.19560,047 shs251,048 shsGELSGelteq$1.66+5.1%$1.82$0.77▼$5.50$14.91MN/A120,634 shs103,101 shsREVBRevelation Biosciences$2.38-6.7%$2.58$2.11▼$168.00$3.91M-0.06222,746 shs206,164 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLRAllarity Therapeutics-2.34%-5.15%-4.23%-6.06%-76.46%CTXRCitius Pharmaceuticals+0.78%-5.84%-33.16%+72.00%-94.30%GELSGelteq-6.21%-8.67%-16.84%+11.27%+157,999,900.00%REVBRevelation Biosciences+2.00%+2.41%+1.59%-73.27%-94.99%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALLRAllarity Therapeutics2.7484 of 5 stars3.54.00.00.02.10.01.3CTXRCitius Pharmaceuticals1.906 of 5 stars3.32.00.00.01.10.81.3GELSGelteqN/AN/AN/AN/AN/AN/AN/AN/AREVBRevelation Biosciences0.4049 of 5 stars0.02.00.00.01.50.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALLRAllarity Therapeutics 3.00Buy$9.00827.84% UpsideCTXRCitius Pharmaceuticals 2.50Moderate Buy$53.004,208.94% UpsideGELSGelteq 0.00N/AN/AN/AREVBRevelation Biosciences 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest REVB, GELS, ALLR, and CTXR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/28/2025ALLRAllarity TherapeuticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$9.006/30/2025CTXRCitius PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.006/9/2025CTXRCitius PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.005/23/2025CTXRCitius PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold5/23/2025CTXRCitius PharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/15/2025CTXRCitius PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00(Data available from 8/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALLRAllarity TherapeuticsN/AN/AN/AN/A$1.62 per shareN/ACTXRCitius PharmaceuticalsN/AN/AN/AN/A$10.25 per shareN/AGELSGelteq$100K156.70N/AN/A$1.30 per share1.28REVBRevelation BiosciencesN/AN/AN/AN/A$27.05 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALLRAllarity Therapeutics-$24.51MN/A0.00N/AN/AN/A-147.94%-90.33%N/ACTXRCitius Pharmaceuticals-$39.14MN/A0.000.98N/AN/A-58.63%-37.67%8/11/2025 (Estimated)GELSGelteq-$2.33MN/A0.00∞N/AN/AN/AN/AN/AREVBRevelation Biosciences-$15.04M-$307.86N/AN/AN/AN/A-299.46%-115.36%8/8/2025 (Estimated)Latest REVB, GELS, ALLR, and CTXR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q3 2025CTXRCitius Pharmaceuticals-$0.76N/AN/AN/A$1.92 millionN/A5/14/2025Q2 2025CTXRCitius Pharmaceuticals-$1.08-$1.27-$0.19-$1.27N/AN/A5/13/2025Q1 2025ALLRAllarity Therapeutics-$8.10-$0.25+$7.85-$0.25N/AN/A5/8/2025Q1 2025REVBRevelation Biosciences-$20.64-$6.33+$14.31-$2.11N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALLRAllarity TherapeuticsN/AN/AN/AN/AN/ACTXRCitius PharmaceuticalsN/AN/AN/AN/AN/AGELSGelteqN/AN/AN/AN/AN/AREVBRevelation BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALLRAllarity TherapeuticsN/A2.662.66CTXRCitius PharmaceuticalsN/A0.370.06GELSGelteqN/A0.79N/AREVBRevelation BiosciencesN/A3.603.60Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALLRAllarity Therapeutics11.53%CTXRCitius Pharmaceuticals16.88%GELSGelteqN/AREVBRevelation Biosciences12.80%Insider OwnershipCompanyInsider OwnershipALLRAllarity Therapeutics0.08%CTXRCitius Pharmaceuticals10.70%GELSGelteqN/AREVBRevelation Biosciences2.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALLRAllarity Therapeutics1015.08 million15.07 millionNot OptionableCTXRCitius Pharmaceuticals2010.63 million9.50 millionOptionableGELSGelteqN/A9.44 millionN/AN/AREVBRevelation Biosciences101.53 million1.50 millionNot OptionableREVB, GELS, ALLR, and CTXR HeadlinesRecent News About These CompaniesRevelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2025August 8 at 6:30 AM | businesswire.comRevelation Biosciences (REVB) to Release Quarterly Earnings on FridayAugust 1, 2025 | americanbankingnews.comRevelation Biosciences Inc. Completes Dosing of Patients in PRIME StudyJuly 16, 2025 | businesswire.comRevelation Biosciences to implement 1-for-3 reverse stock splitJuly 2, 2025 | investing.comRevelation Biosciences Inc. Announces 1-for-3 Reverse Stock Split Effective July 7, 2025 - MorningstarJuly 2, 2025 | morningstar.comMRevelation Biosciences Inc. Announces 1-for-3 Reverse Stock Split Effective July 7, 2025July 1, 2025 | businesswire.comRevelation Biosciences Inc News (REVB) - Investing.comJune 24, 2025 | investing.comRevelation Biosciences, Inc. (REVB) Raises $4M in Public OfferingMay 31, 2025 | finance.yahoo.comRevelation Biosciences sets terms for $4 million public offeringMay 30, 2025 | investing.comRevelation Biosciences, Inc. (REVB) Raises $4M in Public OfferingMay 29, 2025 | insidermonkey.comRevelation Biosciences, Inc. Announces Closing of $4 Million Public OfferingMay 29, 2025 | businesswire.comRevelation Biosciences, Inc. Announces Pricing of $4 Million Public OfferingMay 29, 2025 | finance.yahoo.comRevelation Biosciences board member steps down amid new focusMay 25, 2025 | uk.investing.comRevelation Biosciences Announces Retirement of George Tidmarsh, MD, PhD from Board of DirectorsMay 23, 2025 | businesswire.comREVB On Track and Exploring New MarketsMay 9, 2025 | msn.comRevelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, ...May 8, 2025 | gurufocus.comRevelation Biosciences to Develop Gemini for Infection in Severe Burn PatientsApril 29, 2025 | businesswire.comWhy Revelation Biosciences Inc. (REVB) Went Down On Thursday?April 10, 2025 | msn.comGemini Priming Attenuates Inflammation in Human Peripheral Blood Mononuclear CellsMarch 17, 2025 | businesswire.comRevelation Biosciences to Host Fireside Chat at 37th Annual Roth ConferenceMarch 13, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeREVB, GELS, ALLR, and CTXR Company DescriptionsAllarity Therapeutics NASDAQ:ALLR$0.97 -0.02 (-1.66%) Closing price 04:00 PM EasternExtended Trading$0.98 +0.02 (+1.55%) As of 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.Citius Pharmaceuticals NASDAQ:CTXR$1.23 -0.06 (-4.65%) Closing price 04:00 PM EasternExtended Trading$1.25 +0.02 (+1.22%) As of 06:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.Gelteq NASDAQ:GELS$1.66 +0.08 (+5.06%) As of 04:00 PM EasternGelteq Inc. is a biotechnology company which specializes in the formulation, development and manufacturing of ingestible gel platform designed for nutrient and drug delivery. The Company is focused on advancing and commercializing its delivery solutions within core verticals pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications and sports nutrition. Gelteq Inc. is based in NEW YORK.Revelation Biosciences NASDAQ:REVB$2.38 -0.17 (-6.67%) Closing price 04:00 PM EasternExtended Trading$2.44 +0.06 (+2.48%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Airbnb Beats Earnings, But the Growth Story Is Losing Altitude Dutch Bros Just Flipped the Script With a Massive Earnings Beat Amazon Takes an Equity Stake in IonQ—Any Upside Potential? D-Wave Delivers Growth Shock—Investors Eye Quantum Future Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity? Constellation Energy’s Earnings Beat Signals a New Era AppLovin’s Q2 Miss Spooks Market, But Wall Street Doubles Down DraftKings Posts Record Quarter, Eyes Profitability Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
